Working Note: Nan Shan Life Insurance

Knowledge Snapshot

This file is issuer coverage memory for objective context. Detailed figures are stored primarily in data/nan_shan_life_insurance_key_metrics_20260514.json.

Last updated: 2026-06-23

Issuer Overview

• Nan Shan Life Insurance Company, Ltd. is a major Taiwan life insurer founded in July 1963.
• Official company sources reviewed for the current report describe more than 4,000 employees, more than 30,000 agents, more than 6.7 million policyholders, more than 11.7 million in-force policies, 25 branches, and 291 agency offices.
• The company should be analysed as a life insurer with long-duration policyholder liabilities and a large domestic and offshore investment portfolio.
• Official company homepage disclosures for 2024 showed paid-in capital of NT$147bn, total assets of about NT$5.6tn, and shareholders' equity of NT$356.3bn, with top-three industry positioning for total assets and shareholders' equity.

Core Credit View

• The credit profile combines a large Taiwan insurance franchise, high persistency, investment-grade ratings, and demonstrated capital-market access with material FX, ALM, insurance-liability, and subordinated-capital risks.
• The central constraint is the structure identified by Fitch: US dollar assets exceed US dollar liabilities and are used to back Taiwan-dollar-denominated obligations. Sustained Taiwan-dollar appreciation can pressure earnings, capital, hedge costs, and ratings.
• 2025 capital reinforcement through USD Tier 2 issuance helped stabilise the rating view, but it did not remove the underlying currency-mismatch and ALM issues.
• The Q1 2026 reviewed consolidated financial statements, disclosed on 2026-05-11, were a positive but not view-changing data point: net profit returned to NT$8.5bn, equity rose to NT$372.4bn, and the disclosed net worth ratio improved to 7.04%, but RBC, TW-ICS, Prism, hedging-cost, ALM, CSM, claims, and product-profitability detail remained insufficient for concluding that FX and capital questions have been resolved.

Business and Franchise View

• Nan Shan Life has a long operating history, broad agency distribution, a large policyholder base, and top-tier scale in Taiwan's life insurance market.
• Product scope includes traditional life, health and medical, accident, annuity, investment-linked, foreign-currency, and related insurance products.
• FYP growth is credit-supportive only if product profitability, guarantees, claims, capital consumption, and hedging burden remain manageable. Product growth should not be treated as unconditional credit improvement.
• Nan Shan General Insurance is a wholly owned non-life subsidiary, but current memory does not contain enough standalone non-life financial information to treat it as a major credit driver.

Capital Structure and Structural Points

• Official rating material showed S&P A- / Stable, Taiwan Ratings twAA+ / Stable, and Fitch A- / AA(twn) / Stable as of November 2025.
• Fitch's 2025 rating action affirmed the IFS at A-, Long-Term IDR at BBB+, and USD subordinated dated capital bonds issued by Nanshan Life Pte. Ltd. at BBB.
• Nanshan Life Pte. Ltd. is a Singapore-incorporated wholly owned subsidiary of Nan Shan Life. Its USD Tier 2 subordinated dated capital bonds are guaranteed by Nan Shan Life, but the instruments remain subordinated capital securities rather than senior debt.
• The 2025 USD Tier 2 series totalled USD653mn after an initial USD395mn issue and a USD258mn tap, with a 5.875% coupon and 2041 maturity according to the transaction source.

Liquidity and Funding View

• Nan Shan Life's liquidity and funding analysis should focus on insurance liabilities, investment-asset liquidity, surrender behaviour, hedge costs, cash and cash equivalents, debt maturities, and regulatory capital.
• The investment portfolio is large and dominated by offshore fixed-income assets. Detailed figures are retained in the JSON data file rather than repeated here.
• Monthly self-reported earnings and FYP data are useful for direction, but they are unaudited and can be volatile for insurers.
• The official Q1 2026 reviewed financial statements should be used ahead of the March 2026 monthly self-reported loss when assessing the first-quarter direction. They confirm a positive quarter under the IFRS 17 / IFRS 9 reporting basis, while preserving the need for quarterly trend and regulatory-capital checks.

Credit Strengths

• Large and established Taiwan life-insurance franchise.
• Broad agency network and policyholder base.
• High persistency in the available 2025 data.
• Investment-grade rating recognition from major rating agencies.
• Demonstrated access to international capital markets through the 2025 USD Tier 2 issuance.

Credit Weaknesses

• Material FX and ALM exposure from offshore assets backing Taiwan-dollar obligations.
• Earnings and capital sensitivity to Taiwan-dollar appreciation, hedge costs, market valuations, and unrealized losses.
• Long-duration insurance liabilities with assumption risk around guarantees, surrenders, claims, and liability adequacy.
• Limited current visibility on audited FY2025 detail, ALM gap, guaranteed rates, claims ratios, and detailed hedging profile.
• Tier 2 investors face subordination and capital-instrument risks that are separate from issuer credit.

Rating Watchpoints

• Fitch's removal of Rating Watch Negative in November 2025 indicates stabilisation under its base case, not elimination of FX risk.
• Rating analysis must keep IFS, IDR, national-scale ratings, domestic subordinated ratings, and USD Tier 2 ratings separate.
• Rating pressure could re-emerge if FX losses deplete reserves and capital buffers, capital strength weakens, or profitability remains weak for a prolonged period.

Recurring Analytical Cautions

• Do not rely on company size alone as a credit conclusion.
• Do not infer that a guaranteed Tier 2 security has senior-debt protection.
• Do not use unaudited monthly results as a substitute for annual or interim financial statements.
• Do not assert detailed S&P or Taiwan Ratings rationale until the original reports are obtained.

Reliable Core Sources

• Nan Shan Life official history, homepage, product page, annual financial information, interim consolidated financial statements, monthly financial information, 2024 annual report, and official credit ratings material.
• Nan Shan Life Q1 2026 consolidated financial statements and independent auditors' review report, disclosed 2026-05-11, for the first IFRS 17 / IFRS 9 quarter and restated comparisons.
• Fitch 2025 rating action detail as republished by Reuters / TradingView, pending direct confirmation from the original Fitch page.
• Allen & Gledhill transaction note for the 2025 USD Tier 2 issue and tap.
• data/nan_shan_life_insurance_key_metrics_20260514.json for structured financial, operating, capital, rating, and Tier 2 data.
• data/nan_shan_life_insurance_q1_2026_results_20260623.json for structured Q1 2026 reviewed financial data and credit-read-through tags.

Issuer Notes

This file is issuer coverage memory for research and writing judgment. It is not a work log.

Last updated: 2026-06-23

Ongoing Follow-Up Items

• Track USD/TWD, Taiwan-dollar appreciation pressure, FX valuation reserve, hedging costs, and the Fitch sensitivity around sustained Taiwan-dollar appreciation from the end-3Q25 level.
• Recheck RBC ratio, Fitch Prism score, total equity, total equity plus FX valuation reserve, and the impact of Taiwan's TW-ICS / IFRS 17 capital transition.
• After the Q1 2026 reviewed financial statements, track whether positive net profit, improved equity, and the 7.04% net worth ratio persist in Q2 / H1 2026 or reverse with market, FX, hedging, or liability movements.
• Monitor overseas fixed-income portfolio size, credit quality, duration, unrealized gains/losses, hedge costs, and liquidity under surrender or market stress.
• Monitor insurance contract liabilities, guarantee rates, liability adequacy, lapse / surrender rates, and 13-month and 25-month persistency.
• Track health, accident, medical, and long-term care claims trends, pricing power, repricing lag, and reinsurance protection.

Unresolved Issues and Items to Check Next Time

• Obtain the full audited 2025 annual financial statements and detailed notes. The 2025 Annual Financial Information is useful but should not be treated as a full audited annual report.
• Obtain the full S&P Global Ratings and Taiwan Ratings reports dated 2025-11-26, if accessible, before relying on their detailed rationale or triggers.
• Confirm the original Fitch rating action page or full text for the 2025-11-14 affirmation and Rating Watch Negative removal; current memory relies on a Reuters / TradingView republication for Fitch detail.
• Obtain the USD Tier 2 Offering Circular and trust deed, including coupon deferral, write-down or conversion language, regulatory call, tax call, redemption approval, ranking of the issuer guarantee, and fund-transfer mechanics between Nanshan Life Pte. Ltd. and Nan Shan Life.
• Reconcile the 2025 FYP difference between the NT$82.2bn figure in the Annual Financial Information composition table and the NT$92.997bn cumulative figure in the December 2025 monthly self-reported data.
• Confirm the currency split of insurance liabilities, asset-liability duration gap, guarantee rates, product-level new business value, claims ratios, lapse assumptions, morbidity assumptions, and reinsurance program.
• Confirm CSM movement, new business CSM, insurance service result drivers, hedging cost, and FX valuation reserve movements under the new IFRS 17 / IFRS 9 reporting basis when company materials provide more detail.
• Obtain market price, spread, yield, OAS, same-tenor comparables, and peer insurance Tier 2 comparables before making any relative-value judgment.

Analytical Cautions

• Analyse Nan Shan Life as a life insurer with long-duration policyholder liabilities and a very large investment portfolio, not as a bank or general corporate issuer.
• Keep franchise strength separate from market-risk resilience. Large scale, high persistency, and a broad agency network do not eliminate FX, ALM, hedge-cost, unrealized-loss, surrender, claims, or regulatory-capital risk.
• Treat FYP growth as conditionally positive only after checking product mix, margins, capital consumption, guarantees, claims, and hedging burden.
• Do not infer that offshore fixed-income assets are credit-neutral because they are bonds; their currency, duration, accounting classification, liquidity, hedge cost, and credit-spread sensitivity matter.
• Do not transfer the issuer credit view directly to Tier 2 securities. Subordination, capital character, coupon restrictions, redemption approval, regulatory loss absorption, and guarantee ranking must be assessed separately.
• Distinguish IFS, IDR, national-scale ratings, domestic subordinated-debt ratings, and USD Tier 2 ratings in all report language.

Report Wording Cautions

• Avoid saying or implying that the USD Tier 2 guarantee is equivalent to senior unsecured protection.
• Avoid stating that Nan Shan Life has resolved FX risk. The correct framing is that near-term rating pressure has stabilised after capital reinforcement, while currency mismatch remains a key constraint.
• Avoid describing S&P or Taiwan Ratings triggers unless the original rating reports have been obtained.
• Avoid definitive peer-superiority claims versus Cathay Life, Fubon Life, KGI Life, Taiwan Life, or other Taiwanese insurers without a consistent peer dataset.
• Do not use the March 2026 monthly net loss alone as evidence of credit deterioration; monthly insurer earnings can be volatile and should be checked against quarterly, semi-annual, and annual materials.
• Do not treat the positive Q1 2026 reviewed result as evidence that FX or capital risk has been resolved. The correct framing is that first-quarter profitability and equity presentation improved, while regulatory-capital, FX, ALM, and product-profitability checks remain open.

Follow-Up on Management Strategy, Investment Plans, and Financial Policy

• Confirm whether the company is materially increasing US dollar-denominated policy sales or Taiwan-dollar assets to reduce currency mismatch, and whether this improves economic ALM rather than only new-business mix.
• Check whether capital reinforcement after the USD653mn Tier 2 issuance is recurring, opportunistic, or tied to regulatory-capital transition.
• Monitor capital-management policy, dividend posture, product strategy, hedging approach, and potential changes in risky-asset allocation.
• Monitor whether the IFRS 17 / IFRS 9 presentation changes reported earnings volatility, capital communication, and management's product or asset-allocation incentives.

Items to Check for Ratings and Bond Investors

• Reconfirm Fitch IFS, Long-Term IDR, national ratings, domestic subordinated-debt ratings, and USD Tier 2 rating from original rating-agency sources whenever possible.
• Check RBC, Prism, FX reserve, unrealized gains/losses, capital buffers, and downgrade sensitivities at each update.
• For individual bonds, review issuer, guarantor, ranking, coupon suspension, loss absorption, first call date, step-up, regulatory call, tax call, redemption approval, governing law, and liquidity before making any investment view.